ANALYST-UPGRADE

QNRX

Quoin Pharmaceuticals, Ltd.
BULLISH
Impact 2/10
Processed5mo ago SECanalyst-QNRX-lucidcap-20260504
LUCID CAPITAL MARKETS initiates coverage on QNRX at Buy
Actionable Insight ▲ Bullish

Aggressive traders should watch for a pre-earnings squeeze given 56.7% short interest and a new $43M institutional position. However, Lucid's low accuracy and the stock's deep losses mean this is a high-risk binary event — size accordingly.

DirectionBullish
Final — all horizons settled through T+60d
QNRX ▼ -30.27% at T+60d
LONG call ✗ call lost -30.27% · α vs SPY -33.01% · entry $6.31 → $4.40
Entry anchored
May 4, 02:06 PM ET
via exchange tick
T+1d
+1.90%
call +1.90% · α +0.52%
$6.43
settled 6mo ago
T+5d
-0.48%
call -0.48% · α -2.46%
$6.28
settled 5mo ago
T+20d
-27.73%
call -27.73% · α -32.69%
$4.56
settled 5mo ago
T+60d
-30.27%
call -30.27% · α -33.01%
$4.40
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Lucid Capital Markets initiated coverage on Quanterix (QNRX) with a Buy rating and a $30 price target, representing a 372% upside from the current $6.36 close. The initiation comes just three days before Q1 2026 earnings on May 7, adding a high-stakes timing factor. Lucid has a 36% accuracy rate on 22 calls with a +5.8% average return, placing it below the typical coverage firm. Consensus is heavily bullish — 7 of 8 analysts rate Buy or Strong Buy, with only one Hold. The mean price target is $29.67, median $35, high $40, low $14. Lucid's $30 target is near the consensus mean but below the median. Momentum is positive with 1 upgrade and 0 downgrades in the past 30 days. EPS estimates have been revised up slightly for the current year but remain deeply negative. Insider and congressional activity is absent, but institutional positioning shows Morgan Stanley initiated a new $43.3M position, while UBS nearly exited. Short interest is elevated at 56.7% of float, signaling heavy bearish positioning. The bottom line: a high-upside initiation from a low-accuracy firm with earnings days away — high risk, high reward for aggressive traders.

Impact Score

Base Score
1/7
LLM Adjustment
+1
Final Score
2/10

Consensus & Targets

Buy / Strong Buy
7 (88%)
Hold
1
Sell / Strong Sell
0
Total Analysts
3
Mean PT
$29.67
Median PT
$35.00
High PT
$40.00
Low PT
$14.00
Current Price
$6.36
Implied Upside
+366.5%

Consensus is strongly bullish: 2 Strong Buy, 5 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 8 analysts. The vast majority see significant upside, with only one hold rating providing any caution.

Current price: $6.36. Mean target: $29.67 (+366% upside). Median: $35. High: $40. Low: $14. Lucid's $30 target is slightly below the median but above the mean, placing it in the middle of the bullish consensus range.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-05-04LUCID CAPITAL MARKETSinitiateBuy—
2024-03-15Maxim GroupmaintainBuy$4.00

In the past 30 days, there has been 1 upgrade (this initiation) and 0 downgrades. EPS revisions show a slight upward trend: 1 revision up for the current fiscal year in the last 7 days, and 1 in the last 30 days. However, EPS estimates remain deeply negative (-$5.55 for FY2026).

Earnings Estimates

Next earnings: May 7, 2026

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
+1q$-2.17$-2.17 — $-2.17$0.00↑0 ↓0
+1y$-3.15$-3.15 — $-3.15$0.00↑0 ↓0
0q$-2.26$-2.26 — $-2.26$0.00↑0 ↓0
0y$-5.55$-5.55 — $-5.55$0.00↑1 ↓0

Cross-Platform Signals

Institutional
MORGAN STANLEY — new
Institutional
UBS Group AG — near_exit (-99.2%)
Short Interest
Short: 434,697 | Exempt: 2,009 | TRF Vol: 766,978 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)

Insider trades: none reported. Congressional trades: none. Institutional changes: Morgan Stanley opened a new $43.3M position (bullish signal), while UBS Group AG nearly exited (-99.2% reduction, now only $7K). Short interest is 56.7% of float, extremely high — this suggests heavy bearish positioning that could fuel a short squeeze if earnings surprise positively. The institutional new buy and high short interest converge with the bullish analyst signal, but the near-exit by UBS and low firm accuracy diverge.

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

Report based on filing metadata.

14 reports for QNRX
Performance horizon
40% Hit rate 2 of 5 directional calls best @ T+5▲ +18.63%Aug 28, 2026
Filters
Rows
Reports for QNRX — sortable, filterable
TypeNow
Oct 12, 2026
6d ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$4.36 $4.15▼ −4.82%▼ −4.80%$3.90 (−10.55%)
Sep 2, 2026
6w ago
Insider Cluster
MIXED ★ 6/10
$6.74 $7.87▲ +16.77%▲ +15.72%$3.90 (−42.14%)
Aug 28, 2026
7w ago
8-K
MIXED ★ 6/10
$6.12 $6.22▲ +1.63%▲ +1.93%$3.90 (−36.27%)
Aug 28, 2026
7w ago
Press Release
BEARISH ★ 7/10
$6.12 $6.22▼ −1.63%▼ −1.93%$3.90 (+36.27%)
Aug 28, 2026
7w ago
Press Release
BULLISH ★ 7/10
$6.12 $6.22▲ +1.63%▲ +1.93%$3.90 (−36.27%)
Aug 20, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$5.57 $5.42▼ −2.69%▼ −2.40%$3.90 (−29.98%)
Aug 7, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$4.79 $5.36▲ +11.90%▲ +11.93%$3.90 (−18.58%)
Jun 23, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$3.83 $4.20▲ +9.66%▲ +9.52%$3.90 (+1.83%)
May 7, 2026
23w ago
Press Release
BULLISH ★ 6/10
$6.37 $5.93▼ −6.91%▼ −7.74%$3.90 (−38.78%)
May 5, 2026
23w ago
ANALYST-UPGRADE
BULLISH ★ 2/10
$6.31 $6.43▲ +1.90%▲ +0.52%$3.90 (−38.19%)
Showing 10 of 14

US Market Status

Market Closed — Opens in 5h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 5, 2026